Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Quantum Biopharma (QNTM) EPS (Weighted Average and Diluted) (2019 - 2025)

Quantum Biopharma's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.7 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$0.7 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.7, a N/A change, with the full-year FY2025 number at -$4.71, changed N/A from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.7 in Q4 2025 for Quantum Biopharma, up from -$0.71 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for QNTM hit a ceiling of $0.0 in Q1 2021 and a floor of -$23.94 in Q2 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$3.4 across 5 years, with a median of -$0.55 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 217132247.96% in 2024 and later skyrocketed 94.26% in 2025.
  • Tracing QNTM's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.0 in 2021, then grew by 11.69% to -$0.0 in 2022, then tumbled by 351009573.62% to -$0.04 in 2023, then crashed by 787.1% to -$0.35 in 2024, then plummeted by 102.35% to -$0.7 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for QNTM at -$0.7 in Q4 2025, -$0.71 in Q3 2025, and -$1.37 in Q2 2025.